Skip to main content
. 2013 Nov 19;5(1):42–50. doi: 10.1007/s12672-013-0165-7

Table 3.

Association of tumor characteristics with prolactin receptor expression among 736 women (stratified by menopausal status) with breast cancer from the Polish Breast Cancer Study

Premenopausal N = 142 Postmenopausal N = 594
PRLR staining (negative or low) N (%) PRLR staining (strong) N (%) p Value PRLR staining (negative or low) N (%) PRLR staining (strong) N (%) p Value*
PRL serum levels** N = 349
 Low 5 (17.9) 23 (82.1) 25 (17.9) 115 (82.1)
 High 7 (23.3) 23 (76.7) 0.61 23 (15.5) 125 (84.5) 0.60
Histological type N = 713
 Ductal 27 (22.3) 94 (77.7) 79 (16.7) 394 (83.3)
 Lobular 1 (7.1) 13 (92.7) 0.30 16 (15.2) 89 (84.8) 0.71
Axillary node metastasis N = 716
 Node negative 13 (19.7) 53 (80.3) 49 (14.9) 280 (85.1)
 Node positive 15 (20.6) 58 (79.5) 0.90 45 (18.2) 203 (81.9) 0.30
ER N = 732
 Negative 12 (19.7) 49 (80.3) 38 (20.2) 150 (79.8)
 Positive 17 (21.3) 63 (78.8) 0.82 59 (14.6) 344 (85.4) 0.09
PR N = 731
 Negative 14 (22.2) 49 (77.8) 56 (17.6) 262 (82.4)
 Positive 15 (19.2) 63 (80.8) 0.66 41 (15.1) 231 (84.9) 0.41
HER2 N = 721
 Negative 25 (20.5) 97 (79.5) 79 (15.3) 437 (84.7)
 Positive 4 (22.2) 14 (77.8) 1.0 16 (24.6) 49 (75.4) 0.06
ER/PR N = 730
 ER+ PR+ 13 (20.3) 51 (79.7) 36 (14.4) 214 (85.6)
 ER+ PR− 4 (25.0) 12 (75.0) 23 (15.1) 129 (84.9)
 ER− PR+ 2 (14.3) 12 (85.7) 5 (22.7) 17 (77.3)
 ER− PR− 10 (21.3) 37 (78.7) 0.99 33 (20.0) 132 (80.0) 0.11
ER/PR/HER2 N = 721
ER+ or PR+ and HER2− 18 (19.6) 74 (80.4) 60 (14.6) 351 (85.4)
ER+ or PR+ and HER2+ 1 (50.0) 1 (50.0) 4 (33.3) 8 (66.7)
ER− and PR− and HER2+ 2 (16.7) 10 (83.3) 7 (17.5) 33 (82.5)
ER− and PR− and HER2− 8 (24.2) 25 (75.8) 0.64 24 (20.2) 95 (79.8) 0.13

Not all strata sum to 100 % due to rounding

* p Values from χ 2 test

**Category for PRL levels assigned using median PRL levels for the subset of cases with this measurement